In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IBiomarker/Laboratory analysis, TreatmentActive18 and overNCINCI-2011-03730
CDR0000656038, GOG-9923, U10CA027469, NCT00989651

Trial Description

Summary

This phase I trial is studying the side effects and best dose of ABT-888 when given together with carboplatin, paclitaxel, and bevacizumab in treating patients with newly diagnosed stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboplatin, paclitaxel, and bevacizumab together with ABT-888 may kill more tumor cells.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of ABT-888 when administered with carboplatin, paclitaxel, and bevacizumab using 2 different treatment regimens in patients with newly diagnosed stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cancer.

II. To determine the feasibility of these regimens over 4 courses once the MTD is established.

III. To assess the toxicity of these regimens using NCI CTCAE v4.0 criteria.

SECONDARY OBJECTIVES:

I. To estimate the response rate in patients with measurable disease. II. To estimate the progression-free survival of patients treated with these regimens.

III. To assess the extent of poly-ADP-ribose polymerase (PARP) inhibition in peripheral blood mononuclear cells on day 1 of courses 1 and 2.

IV. To assess genomic BRCA mutation status in all patients and descriptively correlate it with toxicity and efficacy.

OUTLINE: This is a multicenter, dose-escalation study of ABT-888 followed by a feasibility study. Patients are sequentially assigned to 1 of 2 treatment regimens.

REGIMEN I: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes (beginning in course 2) on day 1. Patients also receive oral ABT-888 twice daily on days 1-21. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.

REGIMEN II: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Patients also receive carboplatin, bevacizumab, and ABT-888 as in regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for biomarker analysis.

After completion of study treatment, patients are followed up periodically.

Eligibility Criteria

Inclusion Criteria:

  • Histologically confirmed newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma, including one of the following histologic cell types:
  • Serous adenocarcinoma
  • Endometrioid adenocarcinoma
  • Mucinous adenocarcinoma
  • Undifferentiated carcinoma
  • Clear cell adenocarcinoma
  • Mixed epithelial adenocarcinoma
  • Transitional cell carcinoma
  • Malignant Brenner tumor
  • Adenocarcinoma not otherwise specified
  • Carcinosarcoma
  • Stage II-IV disease defined surgically with either optimal (≤ 1 cm) or suboptimal residual disease
  • Has undergone initial surgery for diagnosis, staging, and cytoreduction within the past 1-12 weeks
  • No current diagnosis of borderline ovarian epithelial tumor (formerly "tumors of low malignant potential") or recurrent invasive ovarian epithelial, primary peritoneal, or fallopian tube cancer treated with surgery only (e.g., stage IA or IB low-grade ovarian epithelial or fallopian tube cancers)
  • Patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently developed an unrelated, new invasive ovarian epithelial, primary peritoneal, or fallopian tube cancer are eligible provided they have not received prior chemotherapy for any ovarian tumor
  • No prior or synchronous primary endometrial cancer, unless all of the following criteria are met:
  • Disease stage ≤ IB
  • No more than superficial myometrial invasion
  • No vascular or lymphatic invasion
  • No poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO grade 3 lesions
  • No history or evidence of primary brain tumor or brain metastases by physical exam
  • GOG performance status 0-2
  • ANC ≥ 1,500/mm^3 (not induced or supported by granulocyte colony-stimulating factors)
  • Platelet count ≥ 100,000/mm^3
  • Creatinine ≤ 1.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN
  • SGOT ≤ 2.5 times ULN
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Albumin ≥ 3.0 g/dL
  • PT/INR ≤ 1.5 (or an in-range INR, usually between 2 and 3, if patient is on a stable dose of therapeutic warfarin)
  • PTT < 1.5 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after completion of study treatment
  • No clinically significant proteinuria (i.e., urine protein:creatinine ratio ≥ 1.0)
  • No neuropathy (sensory and motor) > CTCAE grade 1
  • No acute hepatitis or active infection requiring parenteral antibiotics
  • No serious non-healing wound, ulcer, or bone fracture
  • Patients with granulating incisions healing by secondary intention are eligible provided there is no evidence of fascial dehiscence or infection and the patient undergoes weekly wound examinations
  • No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within the past 28 days
  • No clinical symptoms or signs of GI obstruction and/or requirement for parenteral hydration or nutrition
  • No active bleeding or pathologic condition that carries a high risk of bleeding (e.g., known bleeding disorder, coagulopathy, or tumor involving major vessels)
  • No clinically significant cardiovascular disease, including any of the following:
  • Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg
  • Myocardial infarction or unstable angina within the past 6 months
  • NYHA class II-IV congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • Peripheral ischemia ≥ CTCAE grade 2 (at least brief [< 24 hours] episodes of ischemia managed non-surgically and without permanent deficit)
  • No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 6 months
  • No seizures not controlled with standard medical therapy or other evidence of CNS disease by physical exam
  • No other invasive malignancies within the past 5 years, except for nonmelanoma skin cancer and localized cancer of the breast or head and neck
  • No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
  • No significant traumatic injury within the past 28 days
  • See Disease Characteristics
  • No prior cancer treatment that would contraindicate study therapy
  • More than 5 years since prior chemotherapy for any abdominal or pelvic tumor
  • Prior adjuvant chemotherapy for localized breast cancer is allowed provided it was completed > 3 years ago AND the patient remains free of recurrent or metastatic disease
  • No prior radiotherapy to any portion of the abdominal cavity or pelvis
  • Prior radiotherapy for localized cancer of the breast, head and neck, or skin is allowed provided it was completed > 3 years ago AND the patient remains free of recurrent or metastatic disease
  • More than 28 days since prior major surgical procedure or open biopsy
  • More than 7 days since prior core biopsy
  • No concurrent major surgical procedure

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

Katherine Bell-McGuinnPrincipal Investigator

Trial Sites

U.S.A.
Colorado
  Aurora
 University of Colorado Cancer Center at UC Health Sciences Center
 Susan Davidson Ph: 720-848-0650
Georgia
  Augusta
 Medical College of Georgia Cancer Center
 Sharad Anant Ghamande Ph: 706-721-1663
  Email: cancer@georgiahealth.edu
Illinois
  Chicago
 University of Chicago Cancer Research Center
 Seiko Diane Yamada Ph: 773-834-7424
Iowa
  Iowa City
 Holden Comprehensive Cancer Center at University of Iowa
 David P Bender Ph: 800-237-1225
Maryland
  Baltimore
 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 Deborah K. Armstrong Ph: 410-955-8804
  Email: jhcccro@jhmi.edu
Missouri
  Saint Louis
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 David Gardner Mutch Ph: 800-600-3606
  Email: info@ccadmin.wustl.edu
New York
  New York
 Memorial Sloan-Kettering Cancer Center
 Katherine M Bell-McGuinn Ph: 212-639-7202
Ohio
  Cleveland
 Case Comprehensive Cancer Center
 Steven E. Waggoner Ph: 800-641-2422
 Cleveland Clinic Cancer Center at Fairview Hospital
 Steven E. Waggoner Ph: 800-641-2422
 Cleveland Clinic Taussig Cancer Center
 Steven E. Waggoner Ph: 800-641-2422
 MetroHealth Cancer Care Center at MetroHealth Medical Center
 Peter Graham Rose Ph: 866-223-8100
  Columbus
 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
 David M O'Malley Ph: 866-627-7616
  Email: osu@emergingmed.com
  Mayfield Heights
 Hillcrest Cancer Center at Hillcrest Hospital
 Steven E. Waggoner Ph: 800-641-2422
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Robert S. Mannel Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
Pennsylvania
  Philadelphia
 Fox Chase Cancer Center - Philadelphia
 Lainie P Martin Ph: 215-728-4790
 Gynecologic Oncology Group
 Katherine M Bell-McGuinn Ph: 212-639-7202
Rhode Island
  Providence
 Women and Infants Hospital of Rhode Island
 Cara A Mathews Ph: 401-274-1122
  Email: julie-traylor@ouhsc.edu
Virginia
  Charlottesville
 University of Virginia Cancer Center
 Linda R. Duska Ph: 434-243-6143
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Andrew Poklepovic Ph: 804-628-1939
Wisconsin
  Madison
 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
 David M Kushner Ph: 877-405-6866

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00989651
ClinicalTrials.gov processed this data on January 15, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top